0P48

Moberg Pharma Ab (publ) (0P48)

Moberg Pharma Ab (publ)

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:LSE:0P48

1 2 3 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/06/25	00 : 56	PR Newswire (US)	Moberg Pharma receives SEK 336 million through TO 2 and directed issue to top guarantors - subscription rate in TO 2 of 98%	LSE:0P48	Moberg Pharma Ab (publ)
2024/02/07	16 : 12	UK Regulatory	MOB-015 is launched in Sweden under the brand name Terclara- pharmacies report major demand for the new medication	LSE:0P48	Moberg Pharma Ab (publ)
2024/02/07	16 : 10	UK Regulatory	MOB-015 is launched in Sweden under the brand name Terclara- pharmacies report major demand for the new medication	LSE:0P48	Moberg Pharma Ab (publ)
2023/06/28	18 : 23	PR Newswire (US)	MOB-015 is recommended for approval in EU: Moberg Pharma	LSE:0P48	Moberg Pharma Ab (publ)
2022/03/28	15 : 10	PR Newswire (US)	European marketing authorization application for MOB-015 submitted	LSE:0P48	Moberg Pharma Ab (publ)
2021/12/23	16 : 12	PR Newswire (US)	The Medical Products Agency in Sweden will be reference member state for Moberg Pharma's European registration application	LSE:0P48	Moberg Pharma Ab (publ)
2021/09/22	15 : 22	PR Newswire (US)	Moberg Pharma receives approval from the EMA's Paediatric Committee	LSE:0P48	Moberg Pharma Ab (publ)
2021/02/09	16 : 13	PR Newswire (US)	Moberg Pharmas Year-end report 2020	LSE:0P48	Moberg Pharma Ab (publ)
2021/01/29	21 : 23	PR Newswire (US)	Moberg Pharma: Announcement of terms for the fully guaranteed rights issue in OncoZenge, timetable for the listing and record...	LSE:0P48	Moberg Pharma Ab (publ)
2021/01/29	16 : 37	PR Newswire (US)	New number of shares and votes in Moberg Pharma AB (publ)	LSE:0P48	Moberg Pharma Ab (publ)
2021/01/07	16 : 08	PR Newswire (US)	OncoZenge announces issue of European Patent related to BupiZenge®	LSE:0P48	Moberg Pharma Ab (publ)
2020/12/11	16 : 07	PR Newswire (US)	OncoZenge raises MSEK 10 ahead of spin-off and separate listing	LSE:0P48	Moberg Pharma Ab (publ)
2020/11/30	22 : 33	PR Newswire (US)	Moberg Pharma obtains positive decision from the Swedish Tax Agency regarding the Lex Asea distribution of the shares in Onco...	LSE:0P48	Moberg Pharma Ab (publ)
2020/11/23	16 : 41	PR Newswire (US)	Invitation to market update in Moberg Pharma on November 25th	LSE:0P48	Moberg Pharma Ab (publ)
2020/11/16	23 : 16	PR Newswire (US)	OncoZenge secures approximately SEK 70 million in financing ahead of spin-off and separate listing	LSE:0P48	Moberg Pharma Ab (publ)
2020/11/10	17 : 02	PR Newswire (US)	Extended fiscal year July 2019 - December 2020 Interim report July - September 2020	LSE:0P48	Moberg Pharma Ab (publ)
2020/11/06	16 : 26	PR Newswire (US)	Moberg Pharma decides on fully guaranteed rights issue of approximately SEK 150 million	LSE:0P48	Moberg Pharma Ab (publ)
2020/11/06	16 : 25	PR Newswire (US)	Moberg Pharma intends to distribute and separately list BupiZenge® (BUPI)	LSE:0P48	Moberg Pharma Ab (publ)
2020/10/14	15 : 27	PR Newswire (US)	Moberg Pharma intends to submit a registration application in Europe in 2021	LSE:0P48	Moberg Pharma Ab (publ)
2020/10/14	15 : 24	PR Newswire (US)	Moberg Pharma intends to submit a registration application in Europe in 2021	LSE:0P48	Moberg Pharma Ab (publ)
2020/08/11	15 : 16	PR Newswire (US)	Moberg Pharma: Interim report April - June 2020	LSE:0P48	Moberg Pharma Ab (publ)
2020/07/30	15 : 27	PR Newswire (US)	Appointment of Chief Medical Officer at Moberg Pharma	LSE:0P48	Moberg Pharma Ab (publ)
2020/06/30	15 : 28	PR Newswire (US)	New number of Shares and Votes in Moberg Pharma AB (publ)	LSE:0P48	Moberg Pharma Ab (publ)
2020/06/25	15 : 26	PR Newswire (US)	Moberg Pharma Meets Primary Endpoint in the European Phase 3 Study	LSE:0P48	Moberg Pharma Ab (publ)
2020/06/25	15 : 23	PR Newswire (US)	Moberg Pharma Meets Primary Endpoint in the European Phase 3 Study	LSE:0P48	Moberg Pharma Ab (publ)
2020/05/29	15 : 13	PR Newswire (US)	New Number of Shares and Votes in Moberg Pharma AB (publ)	LSE:0P48	Moberg Pharma Ab (publ)
2020/05/12	15 : 24	PR Newswire (US)	Extended Fiscal Year July 2019 - December 2020 Interim Report January - March 2020	LSE:0P48	Moberg Pharma Ab (publ)
2020/05/05	15 : 14	PR Newswire (US)	Moberg Pharma's Interim Report for July 2019 - March 2020 to be Published on May 12 - Invitation to Teleconference	LSE:0P48	Moberg Pharma Ab (publ)
2020/03/27	17 : 20	PR Newswire (US)	Notice of Extraordinary General Meeting in Moberg Pharma AB (publ)	LSE:0P48	Moberg Pharma Ab (publ)
2020/03/24	05 : 17	PR Newswire (US)	Moberg Pharma Enters Financing Agreement of Up To SEK 216 Million for Further Investments in MOB-015	LSE:0P48	Moberg Pharma Ab (publ)